Journal article icon

Journal article

Bayesian prior elicitation on the efficacy of medical therapies in perianal fistulizing Crohn’s disease

Abstract:
Background & Aims: Robust evidence for most licensed Crohn’s disease therapies is lacking for perianal fistula outcomes due to a lack of dedicated clinical trials. This study aimed to use a Bayesian framework to determine the efficacy of medical therapies for perianal fistulizing Crohn’s disease (PFCD). Methods: A formal prior elicitation exercise was conducted by a group of 11 gastroenterologists and 5 statisticians. Consensus priors were developed leveraging both existing published data and clinical expertise, to determine one-year fistula remission rates for medical treatments with 5 different mechanisms of action (anti-TNF, anti-integrin, anti-IL-12/23, anti-IL-23, and JAK inhibitor). Consensus priors on efficacy of each treatment were determined relative to an elicited consensus prior for placebo control. Results: Consensus priors were obtained for the likelihood of fistula remission at 1 year. The prior mean, together with a 90% prior credible interval, of the one-year fistula remission rate was 0.22 (0.05, 0.46) for placebo, 0.58 (0.09, 0.96) for intravenous infliximab, 0.39 (0.06, 0.82) for adalimumab, 0.53 (0.09, 0.93) for subcutaneous infliximab, 0.24 (0.03, 0.60) for intravenous vedolizumab, 0.44 (0.05, 0.90) for upadacitinib, 0.34 (0.04, 0.77) for ustekinumab, and 0.36 (0.04, 0.82) for anti-IL-23 specific agents. Oral upadacitinib and subcutaneous infliximab demonstrated the highest probability for efficacy, alongside intravenous infliximab. Conclusions: We have conducted the first Bayesian prior elicitation exercise in inflammatory bowel disease. The generated priors could be used to enhance the design and analysis of clinical trials in PFCD by improving estimation of treatment efficacy, minimizing sample sizes, and potentially reducing the need for placebo control arms.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1093/ecco-jcc/jjag061

Authors

More by this author
Role:
Author
ORCID:
0000-0003-3426-6408
More by this author
Role:
Author
ORCID:
0000-0002-3385-2117


More from this funder
Funder identifier:
https://ror.org/03x94j517
Grant:
MC_UU_00002/14 and MC_UU_00040/03
More from this funder
Funder identifier:
https://ror.org/05m8dr349
Grant:
NIHR203312
More from this funder
Funder identifier:
10.13039/100006662


Publisher:
Oxford University Press
Journal:
Journal of Crohn's and Colitis More from this journal
Volume:
20
Issue:
5
Article number:
jjag061
Publication date:
2026-05-10
DOI:
EISSN:
1876-4479
ISSN:
1873-9946


Language:
English
Keywords:
Source identifiers:
4030936
Deposit date:
2026-05-10
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP